BCG and Adenovirus Vaccine Study in Rhesus Macaques
Author Information
Author(s): Magalhaes Isabelle, Sizemore Donata R., Ahmed Raija K., Mueller Stefanie, Wehlin Lena, Scanga Charles, Weichold Frank, Schirru Giulia, Pau Maria Grazia, Goudsmit Jaap, Kühlmann-Berenzon Sharon, Spångberg Mats, Andersson Jan, Gaines Hans, Thorstensson Rigmor, Skeiky Yasir A. W., Sadoff Jerry, Maeurer Markus
Primary Institution: Karolinska Institutet, Solna, Sweden
Hypothesis
Does the combination of BCG vaccination and adenoviral boosts enhance immune responses against tuberculosis in rhesus macaques?
Conclusion
The study found that AFRO-1 induces stronger immune responses compared to BCG in rhesus macaques.
Supporting Evidence
- AFRO-1 showed increased Ag85B-specific IFN-gamma production compared to BCG.
- Stronger T cell proliferation was observed in the CD8alpha/alpha+ T cell subset in AFRO-1 primed animals.
- Polyfunctional T cells were detected in animals primed with AFRO-1.
Takeaway
This study tested a new vaccine strategy for tuberculosis in monkeys and found that one type of vaccine worked better than the other.
Methodology
The study involved priming rhesus macaques with BCG or AFRO-1 followed by two adenoviral boosts, measuring immune responses through blood samples.
Potential Biases
Potential bias due to the small sample size and lack of statistical testing for differences between groups.
Limitations
The study included a limited number of animals, which may affect the generalizability of the results.
Participant Demographics
Female rhesus macaques (Macaca mulatta) aged 2-3 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website